Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Accumulated Expenses of $3.0 billion for Q1 2026, up 1.1% year-over-year from $3.0 billion in Q1 2025, and little changed quarter-over-quarter from $3.0 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 1.1% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (up 1.1% YoY), while the FY2025 annual figure was $3.0 billion, up 6.55% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $3.0 billion, roughly flat from $3.0 billion in the prior quarter.
- The five-year high for Accumulated Expenses was $3.6 billion in Q3 2025, with the low at $1.7 billion in Q1 2022.
- The 5-year median for Accumulated Expenses is $2.8 billion (2024), against an average of $2.7 billion.
- The sharpest annual moves came in 2022 and 2026: Accumulated Expenses surged 42.96% in 2022, then grew 1.1% in 2026.
- Vertex Pharmaceuticals' Accumulated Expenses stood at $2.1 billion in 2022, then gained by 24.86% to $2.7 billion in 2023, then climbed by 5.02% to $2.8 billion in 2024, then gained by 6.55% to $3.0 billion in 2025, then increased by 0.44% to $3.0 billion in 2026.
- Business Quant data shows VRTX's Accumulated Expenses at $3.0 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.18 Bn |
| Mar 31, 2026 | 2.98 Bn |
| Dec 31, 2025 | 2.97 Bn |
| Sep 30, 2025 | 3.61 Bn |
| Jun 30, 2025 | 3.27 Bn |
| Mar 31, 2025 | 2.95 Bn |
| Dec 31, 2024 | 2.79 Bn |
| Sep 30, 2024 | 3.22 Bn |
| Jun 30, 2024 | 2.94 Bn |
| Mar 31, 2024 | 2.80 Bn |
| Dec 31, 2023 | 2.66 Bn |
| Sep 30, 2023 | 2.91 Bn |
| Jun 30, 2023 | 2.60 Bn |
| Mar 31, 2023 | 2.33 Bn |
| Dec 31, 2022 | 2.13 Bn |
| Sep 30, 2022 | 2.26 Bn |
| Jun 30, 2022 | 2.12 Bn |
| Mar 31, 2022 | 1.72 Bn |
| Dec 31, 2021 | 1.68 Bn |
| Sep 30, 2021 | 1.58 Bn |